Unity Biotechnology, Inc.
NASDAQ:UBX
1 (USD) • At close December 24, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0.236 | 4.784 | 0 | 0 | 0 | 1.382 | 0 |
| Cost of Revenue
| 19.699 | 2.18 | 2.88 | 3.449 | 2.663 | 2.18 | 37.373 | 0.153 |
| Gross Profit
| -19.699 | -1.944 | 1.904 | -3.449 | -2.663 | -2.18 | -35.991 | -0.153 |
| Gross Profit Ratio
| 0 | -8.237 | 0.398 | 0 | 0 | 0 | -26.043 | 0 |
| Reseach & Development Expenses
| 20.099 | 36.859 | 38.393 | 67.309 | 70.957 | 58.907 | 37.373 | 13.707 |
| General & Administrative Expenses
| 18.766 | 20.949 | 23.056 | 24.025 | 20.046 | 16.016 | 9.617 | 5.137 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 18.766 | 20.949 | 23.056 | 24.025 | 20.046 | 16.016 | 9.617 | 5.137 |
| Other Expenses
| 5.602 | -0.017 | -0.983 | 0.182 | 4.185 | -0.245 | -0.103 | 0 |
| Operating Expenses
| 44.667 | 57.808 | 61.449 | 91.334 | 91.003 | 74.923 | 46.99 | 18.844 |
| Operating Income
| -44.667 | -57.572 | -56.665 | -93.93 | -89.651 | -79.465 | -45.608 | -18.844 |
| Operating Income Ratio
| 0 | -243.949 | -11.845 | 0 | 0 | 0 | -33.001 | 0 |
| Total Other Income Expenses Net
| 4.807 | 13.103 | -4.06 | 0.086 | 7.474 | 3.067 | 0.952 | -11.56 |
| Income Before Tax
| -39.86 | -59.927 | -60.725 | -93.844 | -82.177 | -76.398 | -44.656 | -30.404 |
| Income Before Tax Ratio
| 0 | -253.928 | -12.693 | 0 | 0 | 0 | -32.313 | 0 |
| Income Tax Expense
| 0 | -2.18 | -0.686 | -1.975 | -7.304 | 3.067 | -1.055 | 11.56 |
| Net Income
| -39.86 | -57.747 | -60.039 | -91.869 | -74.873 | -76.398 | -44.656 | -30.404 |
| Net Income Ratio
| 0 | -244.691 | -12.55 | 0 | 0 | 0 | -32.313 | 0 |
| EPS
| -2.7 | -6.08 | -10.76 | -18.06 | -17.16 | -27.02 | -129.91 | -88.45 |
| EPS Diluted
| -2.7 | -6.08 | -10.76 | -18.06 | -17.16 | -27.02 | -129.91 | -88.45 |
| EBITDA
| -37.283 | -38.731 | -54.668 | -89.103 | -89.651 | -74.218 | -44.304 | -28.068 |
| EBITDA Ratio
| 0 | -238.852 | -12.029 | 0 | 0 | 0 | -32.058 | 0 |